175 related articles for article (PubMed ID: 29246804)
1. Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.
Mauro FR; Foà R
Lancet Oncol; 2018 Jan; 19(1):7-8. PubMed ID: 29246804
[No Abstract] [Full Text] [Related]
2. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Hampel PJ; Rabe KG; Call TG; Ding W; Leis JF; Kenderian SS; Muchtar E; Wang Y; Koehler AB; Parrondo R; Schwager SM; Shi M; Braggio E; Slager SL; Kay NE; Parikh SA
Br J Haematol; 2022 Oct; 199(2):239-244. PubMed ID: 35841338
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib and Venetoclax - Doubling Down on CLL.
Wiestner A
N Engl J Med; 2019 May; 380(22):2169-2171. PubMed ID: 31141640
[No Abstract] [Full Text] [Related]
4. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Kater AP; Levin MD; Niemann CU
N Engl J Med; 2019 Aug; 381(8):788-789. PubMed ID: 31433936
[No Abstract] [Full Text] [Related]
5. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
Jain N; Gandhi V; Wierda W
N Engl J Med; 2019 Aug; 381(8):789. PubMed ID: 31433937
[No Abstract] [Full Text] [Related]
6. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
[No Abstract] [Full Text] [Related]
7. [Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
Ye CJ; Xu WB; Yu Q; Wu C; Huang L; Li JM; Yan H
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):700-702. PubMed ID: 31495144
[No Abstract] [Full Text] [Related]
8. A new triplet for chronic lymphocytic leukaemia: zanubrutinib-venetoclax-obinutuzumab.
Rossi D; De Almeida JM
Lancet Haematol; 2021 Dec; 8(12):e864-e865. PubMed ID: 34826404
[No Abstract] [Full Text] [Related]
9. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
Jain P; Kanagal-Shamanna R; Konoplev S; Zuo Z; Estrov Z
Am J Hematol; 2018 Dec; 93(12):1568-1569. PubMed ID: 30152528
[No Abstract] [Full Text] [Related]
10. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
[No Abstract] [Full Text] [Related]
11. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukaemia.
Hallek M; Shanafelt TD; Eichhorst B
Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Waldron M; Winter A; Hill BT
Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
15. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
16. Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL.
Rogers KA
Clin Cancer Res; 2020 Jul; 26(14):3501-3502. PubMed ID: 32366672
[TBL] [Abstract][Full Text] [Related]
17. The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.
Cosialls AM; Pomares H; Iglesias-Serret D; Saura-Esteller J; Núñez-Vázquez S; González-Gironès DM; de la Banda E; Preciado S; Albericio F; Lavilla R; Pons G; González-Barca EM; Gil J
Haematologica; 2017 Sep; 102(9):1587-1593. PubMed ID: 28619845
[TBL] [Abstract][Full Text] [Related]
18. Can Combination Targeted Therapy Bring About Another Paradigm Shift in Chronic Lymphocytic Leukemia?
Woyach JA
J Clin Oncol; 2019 Oct; 37(30):2711-2713. PubMed ID: 31461378
[No Abstract] [Full Text] [Related]
19. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
20. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
